Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

ADHD Diagnosis and Treatment Guidelines: A Historical Perspective.

Wolraich ML, Chan E, Froehlich T, Lynch RL, Bax A, Redwine ST, Ihyembe D, Hagan JF Jr.

Pediatrics. 2019 Oct;144(4). pii: e20191682. doi: 10.1542/peds.2019-1682.

PMID:
31570649
2.

Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.

Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehmann CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD, Zurhellen W; SUBCOMMITTEE ON CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVE DISORDER.

Pediatrics. 2019 Oct;144(4). pii: e20192528. doi: 10.1542/peds.2019-2528.

PMID:
31570648
3.

Factors Associated with Attention Deficit Hyperactivity Disorder Medication Use in Community Care Settings.

Kamimura-Nishimura KI, Epstein JN, Froehlich TE, Peugh J, Brinkman WB, Baum R, Gardner W, Langberg JM, Lichtenstein P, Chen D, Kelleher KJ.

J Pediatr. 2019 Oct;213:155-162.e1. doi: 10.1016/j.jpeds.2019.06.025. Epub 2019 Jul 9.

PMID:
31300310
4.

Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.

Froehlich TC, Müller-Decker K, Braun JD, Albrecht T, Schroeder A, Gülow K, Goerdt S, Krammer PH, Nicolay JP.

Blood. 2019 Aug 1;134(5):445-455. doi: 10.1182/blood.2019001545. Epub 2019 Jun 5.

PMID:
31167801
5.

Impact of a Cancer Urgent Care Clinic on Regional Emergency Department Visits.

Hong AS, Froehlich T, Clayton Hobbs S, Lee SJC, Halm EA.

J Oncol Pract. 2019 Jun;15(6):e501-e509. doi: 10.1200/JOP.18.00743. Epub 2019 Apr 25.

PMID:
31021677
6.

Attention-Deficit/Hyperactivity Disorder-Related Deficits and Psychostimulant Medication Effects on Comprehension of Audiovisually Presented Educational Material in Children.

Orban SA, Karamchandani TA, Tamm L, Sidol CA, Peugh J, Froehlich TE, Brinkman WB, Estell N, Mii AE, Epstein JN.

J Child Adolesc Psychopharmacol. 2018 Aug 27. doi: 10.1089/cap.2018.0006. [Epub ahead of print]

7.

Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review.

Froehlich TE, Fogler J, Barbaresi WJ, Elsayed NA, Evans SW, Chan E.

Clin Pharmacol Ther. 2018 Oct;104(4):619-637. doi: 10.1002/cpt.1192. Epub 2018 Aug 30.

8.

Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy.

Hsiehchen D, Arasaratnam R, Raj K, Froehlich T, Anderson L.

Oncology. 2018;95(5):319-322. doi: 10.1159/000490617. Epub 2018 Jul 25. Review.

PMID:
30045034
9.

Sluggish Cognitive Tempo as a Possible Predictor of Methylphenidate Response in Children With ADHD: A Randomized Controlled Trial.

Froehlich TE, Becker SP, Nick TG, Brinkman WB, Stein MA, Peugh J, Epstein JN.

J Clin Psychiatry. 2018 Mar/Apr;79(2). pii: 17m11553. doi: 10.4088/JCP.17m11553.

10.

Multimodal Treatment of the School-aged Child With Attention-Deficit/Hyperactivity Disorder.

Froehlich TE, Brinkman WB.

JAMA Pediatr. 2018 Feb 1;172(2):109-110. doi: 10.1001/jamapediatrics.2017.4023. No abstract available.

PMID:
29228151
12.

Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients.

Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY.

Neoplasia. 2017 Oct;19(10):848-855. doi: 10.1016/j.neo.2017.08.004. Epub 2017 Sep 15.

13.

Autism spectrum disorders and their treatment with psychotropic medications in a nationally representative outpatient sample: 1994-2009.

Kamimura-Nishimura K, Froehlich T, Chirdkiatgumchai V, Adams R, Fredstrom B, Manning P.

Ann Epidemiol. 2017 Jul;27(7):448-453.e1. doi: 10.1016/j.annepidem.2017.06.001. Epub 2017 Jun 27.

PMID:
28789776
14.

Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.

Frankel AE, Eskiocak U, Gill JG, Yuan S, Ramesh V, Froehlich TW, Ahn C, Morrison SJ.

Neoplasia. 2017 Apr;19(4):255-260. doi: 10.1016/j.neo.2017.01.010. Epub 2017 Mar 6.

15.

Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.

Gupta A, Shah U, Khine H, Vandergriff T, Froehlich T.

Melanoma Res. 2017 Apr;27(2):171-173. doi: 10.1097/CMR.0000000000000335. No abstract available.

PMID:
28099367
16.

Association of Bisphenol A exposure and Attention-Deficit/Hyperactivity Disorder in a national sample of U.S. children.

Tewar S, Auinger P, Braun JM, Lanphear B, Yolton K, Epstein JN, Ehrlich S, Froehlich TE.

Environ Res. 2016 Oct;150:112-118. doi: 10.1016/j.envres.2016.05.040. Epub 2016 Jun 6.

PMID:
27281688
17.

Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity Disorder.

Becker SP, Froehlich TE, Epstein JN.

J Dev Behav Pediatr. 2016 Jun;37(5):395-404. doi: 10.1097/DBP.0000000000000285.

18.

The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.

Hamzic S, Wenger N, Froehlich TK, Joerger M, Aebi S, Largiadèr CR, Amstutz U.

Pharmacogenomics J. 2017 Jul;17(4):319-324. doi: 10.1038/tpj.2016.23. Epub 2016 Mar 22.

PMID:
27001120
19.

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.

Meulendijks D, Henricks LM, Amstutz U, Froehlich TK, Largiadèr CR, Beijnen JH, de Boer A, Deenen MJ, Cats A, Schellens JH.

Int J Cancer. 2016 Jun 1;138(11):2752-61. doi: 10.1002/ijc.30014. Epub 2016 Feb 19.

20.

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punt CJ, Koopman M, Beijnen JH, Cats A, Schellens JH.

Lancet Oncol. 2015 Dec;16(16):1639-50. doi: 10.1016/S1470-2045(15)00286-7. Epub 2015 Oct 23. Review.

PMID:
26603945
21.

Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.

Kummer D, Froehlich TK, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr CR.

Pharmacogenomics. 2015;16(12):1367-77. doi: 10.2217/pgs.15.81. Epub 2015 Aug 5.

PMID:
26244261
22.

Association of pyrethroid pesticide exposure with attention-deficit/hyperactivity disorder in a nationally representative sample of U.S. children.

Wagner-Schuman M, Richardson JR, Auinger P, Braun JM, Lanphear BP, Epstein JN, Yolton K, Froehlich TE.

Environ Health. 2015 May 28;14:44. doi: 10.1186/s12940-015-0030-y.

23.

Association of the Conners' Kiddie Continuous Performance Test (K-CPT) Performance and Parent-Report Measures of Behavior and Executive Functioning.

Barnard H, Rao R, Xu Y, Froehlich T, Epstein J, Lanphear BP, Yolton K.

J Atten Disord. 2018 Sep;22(11):1056-1065. doi: 10.1177/1087054715578271. Epub 2015 Apr 6.

PMID:
25846228
24.

Expanding medication options for pediatric ADHD.

Froehlich TE, Delgado SV, Anixt JS.

Curr Psychiatr. 2013 Dec;12(12):20-29. No abstract available.

25.

Association of attention-deficit/hyperactivity disorder and conduct disorder with early tobacco and alcohol use.

Brinkman WB, Epstein JN, Auinger P, Tamm L, Froehlich TE.

Drug Alcohol Depend. 2015 Feb 1;147:183-9. doi: 10.1016/j.drugalcdep.2014.11.018. Epub 2014 Dec 2.

26.

Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.

Sistonen J, Büchel B, Froehlich TK, Kummer D, Fontana S, Joerger M, van Kuilenburg AB, Largiadèr CR.

Pharmacogenomics. 2014 Sep;15(13):1653-66. doi: 10.2217/pgs.14.126.

PMID:
25410891
27.

Uncovering a clinical portrait of sluggish cognitive tempo within an evaluation for attention-deficit/hyperactivity disorder: A case study.

Becker SP, Ciesielski HA, Rood JE, Froehlich TE, Garner AA, Tamm L, Epstein JN.

Clin Child Psychol Psychiatry. 2016 Jan;21(1):81-94. doi: 10.1177/1359104514554312. Epub 2014 Oct 17.

28.

Regulating a benzodifuran single molecule redox switch via electrochemical gating and optimization of molecule/electrode coupling.

Li Z, Li H, Chen S, Froehlich T, Yi C, Schönenberger C, Calame M, Decurtins S, Liu SX, Borguet E.

J Am Chem Soc. 2014 Jun 25;136(25):8867-70. doi: 10.1021/ja5034606. Epub 2014 Jun 16.

PMID:
24933522
29.

Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.

Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiadèr CR.

Int J Cancer. 2015 Feb 1;136(3):730-9. doi: 10.1002/ijc.29025. Epub 2014 Jun 27.

30.

Brief report: are autistic-behaviors in children related to prenatal vitamin use and maternal whole blood folate concentrations?

Braun JM, Froehlich T, Kalkbrenner A, Pfeiffer CM, Fazili Z, Yolton K, Lanphear BP.

J Autism Dev Disord. 2014 Oct;44(10):2602-7. doi: 10.1007/s10803-014-2114-x.

31.

Mediators of methylphenidate effects on math performance in children with attention-deficit hyperactivity disorder.

Froehlich TE, Antonini TN, Brinkman WB, Langberg JM, Simon JO, Adams R, Fredstrom B, Narad ME, Kingery KM, Altaye M, Matheson H, Tamm L, Epstein JN.

J Dev Behav Pediatr. 2014 Feb-Mar;35(2):100-7. doi: 10.1097/DBP.0000000000000025.

32.

National trends in psychotropic medication use in young children: 1994-2009.

Chirdkiatgumchai V, Xiao H, Fredstrom BK, Adams RE, Epstein JN, Shah SS, Brinkman WB, Kahn RS, Froehlich TE.

Pediatrics. 2013 Oct;132(4):615-23. doi: 10.1542/peds.2013-1546. Epub 2013 Sep 30.

33.

ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?

Gillardon F, Kremmer E, Froehlich T, Ueffing M, Hengerer B, Gloeckner CJ.

J Neurosci Methods. 2013 Mar 30;214(1):62-8. doi: 10.1016/j.jneumeth.2012.12.015. Epub 2013 Jan 12.

PMID:
23318290
34.

Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study.

Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich TK, Largiader CR, Joerger M.

Cancer Chemother Pharmacol. 2013 Feb;71(2):361-70. doi: 10.1007/s00280-012-2018-4. Epub 2012 Nov 9.

PMID:
23139054
35.

A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants.

Zhu HJ, Brinda B, Froehlich TE, Markowitz JS.

Pharmacogenet Genomics. 2012 Mar;22(3):215-8. doi: 10.1097/FPC.0b013e32834f03eb.

36.

Characteristics of successful recruitment in prospective pediatric pharmacogenetic studies.

Saldaña SN, Hooper DK, Froehlich TE, Campbell KM, Prows CA, Sadhasivam S, Nick TG, Seid M, Vinks AA, Glauser TA.

Clin Ther. 2011 Dec;33(12):2072-81. doi: 10.1016/j.clinthera.2011.10.026. Epub 2011 Dec 2.

37.

Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.

Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB, Graham AJ, Langberg JM, Kahn RS.

J Am Acad Child Adolesc Psychiatry. 2011 Nov;50(11):1129-1139.e2. doi: 10.1016/j.jaac.2011.08.002. Epub 2011 Sep 15.

38.

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.

Amstutz U, Froehlich TK, Largiadèr CR.

Pharmacogenomics. 2011 Sep;12(9):1321-36. doi: 10.2217/pgs.11.72. Review.

39.

Update on environmental risk factors for attention-deficit/hyperactivity disorder.

Froehlich TE, Anixt JS, Loe IM, Chirdkiatgumchai V, Kuan L, Gilman RC.

Curr Psychiatry Rep. 2011 Oct;13(5):333-44. doi: 10.1007/s11920-011-0221-3. Review.

40.

Evidence for higher reaction time variability for children with ADHD on a range of cognitive tasks including reward and event rate manipulations.

Epstein JN, Langberg JM, Rosen PJ, Graham A, Narad ME, Antonini TN, Brinkman WB, Froehlich T, Simon JO, Altaye M.

Neuropsychology. 2011 Jul;25(4):427-441. doi: 10.1037/a0022155. Erratum in: Neuropsychology. 2013 Jan;27(1):106.

41.

Effects of stimulant medication, incentives, and event rate on reaction time variability in children with ADHD.

Epstein JN, Brinkman WB, Froehlich T, Langberg JM, Narad ME, Antonini TN, Shiels K, Simon JO, Altaye M.

Neuropsychopharmacology. 2011 Apr;36(5):1060-72. doi: 10.1038/npp.2010.243. Epub 2011 Jan 19.

42.

Clinical utility of the Vanderbilt ADHD Rating Scale for ruling out comorbid learning disorders.

Langberg JM, Vaughn AJ, Brinkman WB, Froehlich T, Epstein JN.

Pediatrics. 2010 Nov;126(5):e1033-8. doi: 10.1542/peds.2010-1267. Epub 2010 Oct 11.

43.

Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Froehlich TE, McGough JJ, Stein MA.

CNS Drugs. 2010 Feb;24(2):99-117. doi: 10.2165/11530290-000000000-00000. Review.

44.

Association of tobacco and lead exposures with attention-deficit/hyperactivity disorder.

Froehlich TE, Lanphear BP, Auinger P, Hornung R, Epstein JN, Braun J, Kahn RS.

Pediatrics. 2009 Dec;124(6):e1054-63. doi: 10.1542/peds.2009-0738. Epub 2009 Nov 23.

45.

Hybridization probe pairs and single-labeled probes: an alternative approach for genotyping and quantification.

Froehlich T, Geulen O.

Methods Mol Biol. 2008;429:117-33. doi: 10.1007/978-1-60327-040-3_9.

PMID:
18695963
46.

Association of environmental toxicants and conduct disorder in U.S. children: NHANES 2001-2004.

Braun JM, Froehlich TE, Daniels JL, Dietrich KN, Hornung R, Auinger P, Lanphear BP.

Environ Health Perspect. 2008 Jul;116(7):956-62. doi: 10.1289/ehp.11177.

47.

Assessing children with ADHD in primary care settings.

Langberg JM, Froehlich TE, Loren RE, Martin JE, Epstein JN.

Expert Rev Neurother. 2008 Apr;8(4):627-41. doi: 10.1586/14737175.8.4.627. Review.

PMID:
18416664
48.

The time and change test: a simple screening test for dementia.

Inouye SK, Robison JT, Froehlich TE, Richardson ED.

J Gerontol A Biol Sci Med Sci. 1998 Jul;53(4):M281-6.

PMID:
18314567
49.

Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children.

Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS.

Arch Pediatr Adolesc Med. 2007 Sep;161(9):857-64.

PMID:
17768285
50.

Interactive effects of a DRD4 polymorphism, lead, and sex on executive functions in children.

Froehlich TE, Lanphear BP, Dietrich KN, Cory-Slechta DA, Wang N, Kahn RS.

Biol Psychiatry. 2007 Aug 1;62(3):243-9. Epub 2007 Jan 17.

PMID:
17239353

Supplemental Content

Loading ...
Support Center